I-Mab Reports Acceptance Of IND Application In China For Phase 2 Trial With Enoblituzumab

I-Mab (IMAB) said the Center for Drug Evaluation of China National Medical Products Administration has accepted the company's IND application to initiate a phase 2 trial for enoblituzumab in combination with pembrolizumab in patients with selected solid tumors. The phase 2 trial will evaluate the efficacy of the combination of enoblituzumab and pembrolizumab.

I-Mab has in-licensed the rights to develop and commercialize enoblituzumab in Greater China from MacroGenics (MGNX).

Joan Shen, CEO of I-Mab, said: "We will be leveraging the data from clinical trials conducted by MacroGenics to advance the clinical development of enoblituzumab for approval in Greater China."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Meta Platforms Inc., the parent of Facebook, Instagram, and WhatsApp, said it is launching more options on WhatsApp to control their messages and how long they stick around, with default disappearing messages and multiple durations. The latest features are expected to bring more control and privacy on the popular messaging app. Delivery services company DoorDash has introduced ultra-fast grocery deliveries with DashMart in Chelsea, New York City. The company said it aims to deliver in 10-15 minutes and plans to expand its new service in select DoorDash grocery and convenience partners over the next year. With over 2,000 items, DashMart offers a wide assortment of fresh and frozen grocery staples, snacks, household goods, and local products. Ontario, Canada-based Erie Meat Products Ltd. is recalling approximately 1,224 pounds of fully cooked chicken bologna products, according to the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS. The chicken bologna products were imported and distributed into the United States without the benefit of FSIS import reinspection.
Follow RTT